Cargando…

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases

BACKGROUND: Anti-PD-1 has activity in brain metastases (BM). This phase II open labeled non-randomized single arm trial examined the safety and efficacy of combining nivolumab with radiosurgery (SRS) in the treatment of patients with BM from non-small cell lung cancer (NSCLC) and renal cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Philip, Masucci, Laura, Florescu, Marie, Plourde, Marc-Emile, Panet-Raymond, Valerie, Pavic, Michel, Owen, Scott, Masson-Coté, Laurence, Ménard, Cynthia, Routy, Bertrand, Tehfe, Mustapha, Nelson, Kristoff, Guilbert, Francois, Boucher, Olivier, Keshavarzi, Sareh, Blais, Normand, Roberge, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072191/ https://www.ncbi.nlm.nih.gov/pubmed/37025758 http://dx.doi.org/10.1093/noajnl/vdad018

Ejemplares similares

Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)
por: Bahig, Houda, et al.
Publicado: (2022)

Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation
por: Blanc-Durand, Félix, et al.
Publicado: (2021)

Arterial thrombosis and coronavirus disease 2019 in a patient with cancer
por: Nassabein, Rami, et al.
Publicado: (2020)

Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series
por: El Sayed, Rola, et al.
Publicado: (2022)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
por: Gauvin, Camille, et al.
Publicado: (2021)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging
por: Harris, Philippe, et al.
Publicado: (2019)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Radiosurgery for brainstem metastases with and without whole brain radiotherapy: clinical series and literature review
por: Murray, Louise, et al.
Publicado: (2016)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
por: Minniti, Giuseppe, et al.
Publicado: (2019)

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience
por: Quinones, Maria Camila, et al.
Publicado: (2021)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
por: Mizutani, Kosuke, et al.
Publicado: (2018)

Molecular subtypes and prognosis in RCC
por: Beuselinck, Benoit, et al.
Publicado: (2015)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

How Low Should You Go: Choice of Minimum Dose Prescription in Cranial Radiosurgery
por: Roberge, David, et al.
Publicado: (2015)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
por: Shah, Ruchitbhai, et al.
Publicado: (2019)

Cardiac embolization of an implanted fiducial marker for hepatic stereotactic body radiotherapy: a case report
por: Hennessey, Hooman, et al.
Publicado: (2009)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

The Multifaceted Roles of RCC1 in Tumorigenesis
por: Ren, Xuanqi, et al.
Publicado: (2020)

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study
por: Ahmed, Kamran A., et al.
Publicado: (2021)

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
por: Hasanov, Elshad, et al.
Publicado: (2023)

Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report
por: Chennouf, Anas, et al.
Publicado: (2017)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer
por: Désilets, Audrey, et al.
Publicado: (2023)

Initial clinical experience with frameless optically guided stereotactic radiosurgery/radiotherapy in pediatric patients
por: Keshavarzi, Sassan, et al.
Publicado: (2009)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
por: Liguori, Luigi, et al.
Publicado: (2023)

The effect of almonds on anthropometric measurements and lipid profile in overweight and obese females in a weight reduction program: A randomized controlled clinical trial
por: Abazarfard, Zohreh, et al.
Publicado: (2014)

Association of Amplitude and Stability of Circadian Rhythm, Sleep Quality, and Occupational Stress with Sickness Absence among a Gas Company Employees—A Cross Sectional Study from Iran
por: Zare, Rezvan, et al.
Publicado: (2017)

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis
por: Bodensohn, Raphael, et al.
Publicado: (2023)

Isolated Scalp Nodule in Patient with Undiagnosed RCC
por: Pan, David, et al.
Publicado: (2006)

Identification of RCC Subtype-Specific microRNAs–Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data
por: Kajdasz, Arkadiusz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fol90uu8m4t6i99r477kr8mes6